Tekturna® (aliskiren) – First-time generic (authorized generic)

- On March 4, 2019, PDL BioPharma announced the launch of an authorized generic version of Tekturna (aliskiren) tablets.
  - Prasco, under an agreement with PDL’s wholly owned subsidiary, Noden Pharma, carried out the launch of the authorized generic.

- Tekturna is approved for the treatment of hypertension in adults and children 6 years of age and older, to lower blood pressure.

- Aliskiren is also available as a brand fixed-dose combination tablet with hydrochlorothiazide (Tekturna HCT®).
  - Tekturna HCT is approved for the treatment of hypertension, in patients not adequately controlled with monotherapy or as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.

- Tekturna carries a boxed warning for fetal toxicity.